EVIDENCE LIBRARY
Adult ICU Withdrawal Review Identified Benzodiazepine Co-Infusion as a Complicating Exposure
An adult ICU review links withdrawal assessment to opioid reduction, sedative co-exposure, and inconsistent diagnostic definitions.
A narrative review of iatrogenic opioid withdrawal in adult intensive care describes benzodiazepine co-infusion as one of several relevant factors. It also emphasizes that adult ICU withdrawal lacks a well-accepted standardized diagnostic tool.
What the reviewed studies reported
The authors discuss eight studies and report withdrawal frequencies ranging from 15% to 40% among patients requiring opioid infusions. Settings included medical, surgical, trauma, and burn ICUs, often with additional sedatives. Predictors varied, with attention to infusion duration, speed of opioid reduction, and benzodiazepine co-administration.
Why a combined exposure requires a timeline
When opioids and benzodiazepines are both changed, agitation or autonomic signs cannot automatically be assigned to a single drug. Critical illness, delirium, pain, and other medication changes can overlap with withdrawal manifestations. A co-infusion associated with withdrawal in a study may reflect exposure complexity or treatment intensity as well as a specific pharmacological contribution.
Limits on numerical interpretation
The reported 15%–40% range is not a pooled risk for all hospitalized patients or a benzodiazepine-only withdrawal incidence. Definitions and populations differed. In an individual review, reconstruct administration and reduction rates for both drug classes, then compare the onset and course of symptoms with the documented clinical assessments. The review’s discussion of treatment approaches describes published practice; it does not establish one taper or diagnostic threshold for every adult ICU patient.
Source and scope
This original analysis uses the supplied paper: Iatrogenic opioid withdrawal syndromes in adults in intensive care units a narrative review. The interpretation above separates the authors’ findings from their implications for evidence review.
Explore related material through this site’s benzodiazepine articles and remimazolam research discussions.